On 10 March, China Resources Sanjiu announced its financial results for the full year of 2015. During the year, China Resources Sanjiu achieved revenue of RMB7,900 million, representing an increase of 8.57% year-on-year. The pharmaceutical industry contributed revenue of RMB7,417 million, representing an increase of 9.30%. Profit attributable to shareholders of the Company reached RMB1,249 million, representing an increase of 20.59% year-on-year. Net cash flow from operating activities was RMB1,260 million, representing an increase of 6.37%.

In 2015, challenged by slower industry growth, China Resources Sanjiu implemented timely adjustment of its business portfolio, optimization of its resources allocation and enhancement of its competition strategy. As a result, it achieved better-than-industry-average growth in its major business segments. Meanwhile, the Company continued to improve its pipeline of self-medication products and optimize its product portfolio. In addition, it strengthened its “1+N” brand strategy, according to which it manages its brands in different brand families. The Company estaliblished an initial structure of the product line of its “Big Health” business and launched 5 “Big Health” products including red sugar ginger tea. The Company’s prescription drug business was adaptive to industry changes. Such adaptability empowered it with the ability to grasp rising market opportunities. The Company also adjusted its product portfolio and management model, strengthened its academic studies, and enhanced its product resources. In addition, it gained ownership of various drug products including quality oral antibiotics from the acquisition of Zhejiang Zhongyi Pharmaceutical.